My lab is developing inhibitors of the human 60 kilodalton heat shock protein (HSP60) chaperonin system as a mechanistically unique anti-cancer strategy.


  • Exploiting the GroEL/ES chaperonin system as a mechanistically novel antimicrobial target
  • Modulation of molecular chaperones and protein homeostasis for the development of oncology therapeutics

Dr. Johnson has received industrial and academic training in research throughout the preclinical drug discovery and development process, from target identification, validation, and high-throughput screening, to in vitro and in vivo hit-to-lead optimization.  

Subject Area:

  • Biochemistry & Molecular Biology.
Biochemistry, Molecular Biology, Oncology, Cellular Biochemistry, Molecular Biochemistry
PharmD, Scripps Research Institute, 2008
PhD, Scripps Research Institute, Chemistry, 2006
BS, University of Victoria, Chemistry, 2001